Yakutsk

Researchers are conducting an observational multicenter cross-sectional study to better understand the characteristics of adults with uncontrolled severe asthma in Russia who are not receiving biological therapy. The study aims to collect detailed information on the epidemiology, clinical features, treatment patterns, and demographics of these patients across different regions of the Russian Federation, which vary widely in population composition and environmental factors. The study will help fill the gap in data about severe asthma in Russia, especially in patients treated according to standard care but excluding biologics. The study plans to include 5,000 adult patients from about 50 outpatient centers across 50 regions of Russia. It will collect routine clinical data without altering standard medical care or introducing any new diagnostic or therapeutic procedures. The study design includes one visit per patient to gather demographic, clinical, and treatment information, focusing on patients with uncontrolled severe asthma receiving standard treatments like inhaled corticosteroids with other medications but not biological agents. Participants will provide data through medical records and assessments such as the Asthma Control Questionnaire. Researchers will analyze patterns of drug use, clinical characteristics including comorbidities, blood counts, immunoglobulin levels, and lifestyle factors. The study will characterize patients' demographics, treatment trends, and asthma control status from June 2024 to June 2027. Safety monitoring is observational, with no intervention beyond routine care, and the total participation involves a single study visit.

Researchers are studying how Lipoprotein(a) (Lp(a)) levels are distributed among patients in Russia with Atherosclerotic Cardiovascular Disease (ASCVD) and examining the link between high Lp(a) levels and the risk of cardiovascular disease. The study includes patients with a history of heart attacks, strokes, or other vascular conditions to better understand this relationship. The study has several phases. Phase I involves a cross-sectional study measuring Lp(a) levels in ASCVD patients. Phase II includes a non-interventional, prospective cohort study following the same patients, along with cross-sectional and cohort studies involving their relatives. Various drugs including statins (Atorvastatin, Simvastatin, Rozuvastatin), Ezetimibe, Niacin, fibrates (Ciprofibrate, Fenofibrate, Bezafibrate), PCSK9 inhibitors (Evolocumab, Alirocumab), and small interfering RNA (Inclisiran) are monitored as part of the research. Participants will undergo assessments of their Lp(a) levels and cardiovascular events over 24 months. Researchers will track the percentage of patients with Lp(a) levels above a specific threshold and compare cardiovascular event rates between groups. The study also involves collecting medical history and monitoring safety. The total participation duration includes initial screening and follow-up periods as outlined in the study phases.

Researchers are studying the presence and types of other health conditions in patients having abdominal surgery to better understand and categorize the risk of complications after surgery. The goal is to identify which existing diseases independently predict such risks, as this knowledge is important for informed consent and planning preventive care. The study focuses on adults with certain physical health statuses undergoing planned operations, noting that while anesthesia risks have decreased, complications remain a significant concern worldwide. The study collects detailed information before surgery about patient age, gender, physical status (ASA classification), various chronic diseases like heart, lung, kidney, neurological disorders, and diabetes, as well as treatments the patient is receiving. It also records the type and severity of different abdominal surgeries and anesthesia methods used. Data is gathered uniformly from multiple centers and entered into an electronic database. The study includes patients operated on within defined days and monitors them until hospital discharge. Participants will have their health and surgical data collected and tracked, including cognitive function, respiratory and cardiac risk scales, and kidney and liver function. Postoperative complications occurring within 7 days of surgery are the main outcomes measured. The study plans to enroll a large number of patients to develop reliable risk prediction models, with ongoing data analysis using statistical methods to identify significant predictors. Results will be validated with additional patient groups to improve accuracy and clinical usefulness.

Researchers are conducting an observational surveillance study to identify the genetic types of rickettsia bacteria causing rickettsioses in patients from various regions of Russia. The study focuses on patients with diagnosed or suspected tick-borne rickettsioses. It aims to link genetic information of the bacteria with patients' medical histories, disease progression, symptoms, and treatments to find clinical patterns specific to different causative agents. The study is non-interventional and has received ethical committee approval. No changes are made to patients' routine treatment or diagnostic procedures during the study. Biological samples such as blood, plasma, buffy coat, serum, or eschar swabs collected during standard diagnostics are used for genetic analysis of the rickettsia species. These residual diagnostic samples are collected only after patients or their legal representatives give written informed consent. Physicians complete individual case report forms to record relevant medical information for each participant. Participants provide informed consent, and their medical history, symptoms, disease course, and treatments are recorded. The genetic typing of rickettsia bacteria is performed within up to 4 weeks after sample collection. The study monitors these genetic findings alongside clinical data to improve understanding of rickettsioses. There is no intervention or alteration in patient care, and the study respects current medical standards throughout its observation period.